Redeye: Episurf Medical Q4 - First steps for the US market

Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA approval for its Episealer Patellofemoral System, marking its first steps on US soil. Sales were in line with our estimates, albeit still at low figures. OPEX came in 19% higher, though without any reason for concern going forward.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Episurf Medical Q4 - First steps for the US market